Recent Updates
Recently added Catalysts
BFRG Positive Sentiment Score: 70/100

BullFrog AI Files 2022 Annual Report on Form 10-K Gaithersburg, MD

Key Takeaway: BullFrog AI Holdings, Inc. has filed its 2022 Annual Report on Form 10-K, addressing prior compliance issues with Nasdaq. The CEO noted that this filing largely mirrored their S-1 IPO filing, which caused the delays. The completion of the filing is expected to prevent future delays in submissions. The company is recognized for its application of machine learning in precision medicine, particularly through its proprietary bfLEAP AI platform.

Market Sentiment Analysis

POSITIVE FACTORS

  • Completion of 10-K filing rectifies compliance issues with Nasdaq.
  • Use of bfLEAP platform aims to reduce development costs and improve patient outcomes.
  • Company collaborates with leading institutions like Johns Hopkins for AI-driven drug development.

CONCERNS & RISKS

  • Initial delay in filing due to the complexity of the first-time submission.
  • Received compliance notice from Nasdaq for not meeting filing deadlines.

Full Press Release Details

AI Files 2022 Annual Report on Form 10-K
MD - April 25, 2023 - BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"),
a digital technology company using machine learning to usher in a new era of precision medicine, today announced it filed its Form
10-K with the Securities and Exchange Commission ("SEC") for its year ended December 31, 2022.
our 10-K largely mirrored the S-1 we filed for our IPO, the first-time nature of this filing required additional work and resources that
delayed its official submission to the SEC, which prompted a compliance notice from Nasdaq. We are pleased to report that the completion
of the 10-K filing has rectified this situation, and we do not anticipate similar delays with future filings," said BullFrog AI's
founder and CEO Vin Singh.
AI received notice from Nasdaq on April 20, 2023, notifying the Company that it was not in compliance with the periodic filing requirements
for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because the Company's Annual Report on Form 10-K for the year
ended December 31, 2022 was not filed with the Securities and Exchange Commission by the required due date. The Company
is now in compliance with Nasdaq Listing Rule 5250(c)(1).
AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with
leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using
its proprietary bfLEAP artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals
and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP for use at
several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the
overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek
to receive the therapies they need.
more information visit BullFrogAI at
press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about
future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events
or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business
prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those
that use terminology such as "may," "should," "expects," "anticipates," "contemplates,"
"estimates," "believes," "plans," "projected," "predicts," "potential,"
or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider
various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially
from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press
release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ
materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives might not occur.
BullFrog AI Holdings, Inc.

Frequently Asked Questions

What did BullFrog AI file with the SEC?

BullFrog AI filed its Form 10-K for the year ended December 31, 2022.

Why was BullFrog AI's 10-K filing delayed?

The delay was due to the complexities of an initial filing, requiring more resources.

What is BullFrog AI's main focus?

BullFrog AI focuses on using machine learning for precision medicine in drug development.

How does BullFrog AI assist in drug development?

They use their bfLEAP AI platform to predict patient responses to therapies.

Is BullFrog AI now compliant with Nasdaq requirements?

Yes, BullFrog AI is currently in compliance with Nasdaq Listing Rule 5250(c)(1).

Last updated: Apr 25, 2023